Manorama Industries' board approved raising up to ₹500 crore through Qualified Institutional Placements (QIP) or other securities on March 12, 2026, with a postal ballot notice to shareholders (cut-off March 13), following explosive Q3 FY26 results where consolidated PAT surged 113% YoY to ₹68.2 crore on 73% revenue growth to ₹362.5 crore.

Manorama QIP Fundraiser – Key Details

Use of Proceeds: Not disclosed – typical QIP uses include capex, working capital, debt repayment, acquisitions.

Manorama's Growth Story Justifying the Raise

Q3 FY26 Blockbuster Results:

• Revenue: ₹362.5 Cr (+73.3% YoY) vs ₹209.2 Cr
• Net Profit: ₹68.2 Cr (+113.1% YoY) vs ₹29.53 Cr
• EBITDA: ₹109.17 Cr (+91.16% YoY)
• EPS: ₹11.43 vs ₹4.96 (strong earnings momentum)

Business: Plant-based specialty oils & fats manufacturer (margarines, shortenings, cocoa butter equivalents, oleochemicals) with capacity expansions underway and export focus to Europe, US markets.

Stock Performance:

• 52-week range: ₹849.95 (Apr 2025) to ₹1,760 (Jul 2025)
• YTD: -0.3%, 1-month: -7%, recent profit booking after rally

Strengths of Manorama's ₹500 Cr QIP

• Funding growth: ₹500 Cr supports capacity expansion, new products, exports after Q3 PAT +113%

• QIP efficiency: Targets institutions for quick execution vs lengthy FPO​
• Strong balance sheet: Funds capex without excessive debt (D/E likely improves)
• Export tailwinds: Specialty fats demand from Europe/US chocolate, bakery sectors
• Proven execution: Delivered 73% revenue growth FY26 despite global headwinds

Risks Around Manorama QIP

• Dilution pressure: ₹500 Cr at ₹1,325/share = ~37.7 lakh new shares (~4.8% equity expansion)
• High valuation: P/E likely 100x+ post-Q3; QIP pricing at discount could pressure existing shareholders
• Execution risk: Capex must deliver targeted ROCE or justify premium multiples
• Commodity exposure: Palm oil, shea butter price volatility impacts margins
• Short-term price reaction: QIP announcements often trigger 5-10% correction on supply overhang